
By StoryTrading
BioCryst’s (NASDAQ:BCRX) stock price hit 15-year highs since our article was published on Benzinga earlier this month, but with the oral prophylactic treatment provider’s 2021 financial results due out this Wednesday, some traders may be wondering whether it’s time to take some money off the table.